TARGET AUDIENCE
This educational activity is intended for the multidisciplinary care team (cardiologists, hematologists, hematologist-oncologists, nephrologists, geneticists, pathologists, neurologists, surgeons, imagers, primary care physicians), and other members of the health care team (nurses, PAs) who see patients with amyloidosis.

PROGRAM OVERVIEW
The goal of this initiative is to strengthen regional care networks to support optimal diagnosis, management, and monitoring of patients with suspected and confirmed amyloidosis. The curriculum emphasizes comparing evidence-based treatment options, applying best practices in care planning, and clarifying the distinct roles of clinical team members in patient management. Participants will explore monitoring strategies, assessment methods, and team-based approaches to address ongoing disease burden and optimize long-term outcomes.

Upon completion of this activity, the learners should be able to:

• Identify common issues for clinical team members in the diagnostic process for amyloidosis
• Differentiate amyloidosis genotypes and phenotypes, including typical symptomatology
• Outline multidisciplinary strategies for confirming amyloidosis diagnosis
• Compare and contrast treatment approaches for amyloidosis
• Utilize best practices in amyloidosis care to establish treatment plans for patients with confirmed amyloidosis
• Correspond clinical team members with their roles in the optimal management of amyloidosis
• Describe importance of post-diagnostic monitoring to patients with amyloidosis
• Outline available assessment approaches of treatment for patients with amyloidosis
• Select team-based assessment approaches for the monitoring of ongoing disease burden

PLANNING COMMITTEE
Daniel Lenihan, MD, FACC
Director of Cardio-Oncology and Heart Failure
Saint Francis Healthcare System/Cape Cardiology Group
Cape Girardeau, MO

Heather Landau, MD
Associate Professor of Medicine
Hematology/Oncology
Memorial Sloan Kettering Cancer Center/Weill Cornell Medicine
New York, NY

Josh Mitchell, MD, MSCI, FACC, FICOS
Associate Professor of Medicine
Director, Cardio-Oncology Center of Excellence
Director, Cardio-Oncology Fellowship
Co-Director, Amyloid Center of Excellence
Washington University School of Medicine
Barnes-Jewish Hospital
St. Louis, MO

Keith Stockerl-Goldstein, MD
Professor of Medicine
Division of Oncology
Washington University School of Medicine
Bone Marrow Transplant Specialist, Medical Oncologist
Siteman Cancer Center
St. Louis, MO

Margot Davis, MD
Clinical Associate Professor
Director of Cardio-Oncology Program
St. Paul's Hospital
Vancouver, BC, Canada

Richard Cheng, MD
Professor of Medicine
Advanced Heart Failure & Transplant Cardiology
University of Washington Medical Center/UW Heart Institute
Seattle, WA

ST. LOUIS FACULTY

Alicia Henao Uribe, MD
Medical Oncologist and Hematologist
Saint Francis Healthcare System/Cape Medical Oncology
Cape Girardeau, MO

Daniel Lenihan, MD, FACC
Director of Cardio-Oncology and Heart Failure
Saint Francis Healthcare System/Cape Cardiology Group
Cape Girardeau, MO

Krishna Rao, MD
Associate Professor of Medicine
Hematology/Oncology
SIU School of Medicine/Simmons Cancer Institute at SIU Medicine
Springfield, IL

Jonathan Moreno, MD, PhD
Assistant Professor of Medicine
Cardiovascular Division
Washington University School of Medicine
Barnes-Jewish Hospital
St. Louis, MO

Josh Mitchell, MD, MSCI, FACC, FICOS
Associate Professor of Medicine
Director, Cardio-Oncology Center of Excellence
Director, Cardio-Oncology Fellowship
Co-Director, Amyloid Center of Excellence
Washington University School of Medicine
Barnes-Jewish Hospital
St. Louis, MO

Keith Stockerl-Goldstein, MD
Professor of Medicine
Division of Oncology
Washington University School of Medicine
Bone Marrow Transplant Specialist, Medical Oncologist
Siteman Cancer Center
St. Louis, MO

Martin W. Schoen, MD, MPH
Assistant Professor of Medicine
Saint Louis University
Hematologist/Oncologist and Hospitalist
St. Louis Veterans Affairs Medical Center
St. Louis, MO

Mukul Bhattarai, MD
Assistant Professor of Clinical Internal Medicine
SIU School of Medicine
Cardiovascular Medicine
Springfield Memorial Hospital
Springfield, IL

SEATTLE FACULTY

David Zhang, MD, PhD, FACP, FACC
Heart Failure Cardiologist
Franciscan Heart & Vascular Associates at St. Joseph Medical Center
Tacoma, WA

Deirdre Mooney, MD
Advanced Heart Failure & Transplant Cardiology Attending Physician
Sacred Heart Medical Center
Providence Medical
Spokane, WA

Joseph Rosales, MD
Executive Medical Director, Cancer Services
Virginia Mason Franciscan Health
Seattle, WA

Kara Cicero, MD, MPH
Assistant Professor, Clinical Research Division
Fred Hutch Cancer Center
Assistant Professor, Division of Hematology and Oncology
University of Washington School of Medicine
Seattle, WA

Kavita Khaira, MD
Acting Assistant Professor of Medicine
University of Washington
VA Puget Sound Health Care System
Seattle, WA

Nick Burwick, MD
Associate Professor of Medicine
Division of Hematology and Oncology
University of Washington
VA Puget Sound Health Care System
Seattle, WA

Richard Cheng, MD
Professor of Medicine
Advanced Heart Failure & Transplant Cardiology
University of Washington Medical Center / UW Heart Institute
Seattle, WA

This activity is jointly provided by The France Foundation and the International Cardio-Oncology Society.

In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Physicians: The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The France Foundation designates this activity for 1.0 nursing contact hours.

Physician Assistants: The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Pharmacists: This application-based activity qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other health care professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and International Cardio-Oncology Society (IC-OS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and IC-OS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, TFF and IC-OS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and IC-OS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

TFF and IC-OS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and IC-OS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by an independent medical educational grant from Amyloidosis Foundation, Alnylam U.S., Inc, BridgeBio Pharma, Inc, and Janssen Scientific Affairs, LLC.

The France Foundation and IC-OS present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, IC-OS, and the commercial supporter(s) assume no liability for the information herein.